ATE525091T1 - Zusammensetzungen und verfahren zur regulierten proteinexpression im darm - Google Patents

Zusammensetzungen und verfahren zur regulierten proteinexpression im darm

Info

Publication number
ATE525091T1
ATE525091T1 AT01923894T AT01923894T ATE525091T1 AT E525091 T1 ATE525091 T1 AT E525091T1 AT 01923894 T AT01923894 T AT 01923894T AT 01923894 T AT01923894 T AT 01923894T AT E525091 T1 ATE525091 T1 AT E525091T1
Authority
AT
Austria
Prior art keywords
methods
compositions
intestinal
protein expression
regulated protein
Prior art date
Application number
AT01923894T
Other languages
English (en)
Inventor
Timothy Kieffer
Anthony T Cheung
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Application granted granted Critical
Publication of ATE525091T1 publication Critical patent/ATE525091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01923894T 2000-03-13 2001-03-12 Zusammensetzungen und verfahren zur regulierten proteinexpression im darm ATE525091T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18879600P 2000-03-13 2000-03-13
US25446400P 2000-12-08 2000-12-08
PCT/IB2001/000722 WO2001068828A2 (en) 2000-03-13 2001-03-12 Compositions and methods for regulated protein expression in gut

Publications (1)

Publication Number Publication Date
ATE525091T1 true ATE525091T1 (de) 2011-10-15

Family

ID=26884471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01923894T ATE525091T1 (de) 2000-03-13 2001-03-12 Zusammensetzungen und verfahren zur regulierten proteinexpression im darm

Country Status (11)

Country Link
US (3) US7335646B2 (de)
EP (2) EP1274464B1 (de)
JP (1) JP5291278B2 (de)
CN (1) CN102151337B (de)
AT (1) ATE525091T1 (de)
AU (1) AU784499B2 (de)
CA (1) CA2403205A1 (de)
DK (1) DK1274464T3 (de)
ES (1) ES2374061T3 (de)
NZ (1) NZ521199A (de)
WO (1) WO2001068828A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
AU2003298801B9 (en) * 2002-12-02 2008-07-31 Gi Dynamics, Inc. Bariatric sleeve
US7608114B2 (en) 2002-12-02 2009-10-27 Gi Dynamics, Inc. Bariatric sleeve
US7815589B2 (en) 2003-12-09 2010-10-19 Gi Dynamics, Inc. Methods and apparatus for anchoring within the gastrointestinal tract
GB0408103D0 (en) * 2004-04-08 2004-05-12 Crusade Lab Ltd Novel herpes simplex viruses
EP1882044A1 (de) 2005-05-11 2008-01-30 sanofi-aventis Verwendung von gip gene promoter polymorphismus.
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
US9381273B2 (en) * 2008-01-31 2016-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scaffolds with oxygen carriers, and their use in tissue regeneration
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US20140112895A1 (en) * 2010-10-08 2014-04-24 Universiti Putra Malaysia Glp-1 promoter mediated insulin expression for the treatment of diabetes
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3272877A1 (de) * 2016-07-18 2018-01-24 ETH Zurich B-zell-mimetische zellen
US20190282710A1 (en) * 2016-07-18 2019-09-19 Eth Zurich B-cell-mimetic cells
AU2018206304A1 (en) 2017-01-06 2019-07-04 Stabilitech Biopharma Ltd Virus

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562421B1 (fr) 1984-04-09 1989-02-17 Sandoz Sa Perfectionnements a la therapie par l'interleukine
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ES2039203T3 (es) 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
WO1992005266A2 (en) 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
WO1993019660A1 (en) 1992-04-03 1993-10-14 Baylor College Of Medicine Gene therapy using the intestine
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US6001941A (en) * 1992-11-19 1999-12-14 Mitsui Chemicals, Inc. Ethylene α-olefin copolymer obtained by copolymerizing ethylene with an α-olefin
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
CA2165162C (en) 1993-06-14 2000-05-23 Hermann Bujard Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
JPH09510601A (ja) 1993-11-12 1997-10-28 ケース・ウエスタン・リザーブ・ユニバーシティ ヒト遺伝子治療用のエピソーム発現ベクター
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
GB9502830D0 (en) * 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5837693A (en) * 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5695977A (en) 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
AU5321299A (en) 1998-07-28 2000-02-21 Advanced Tissue Sciences, Inc. Genetically engineered cells and tissues
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
FR2782732A1 (fr) * 1998-08-28 2000-03-03 Transgene Sa Systeme d'expression inductible
CA2364417C (en) 1999-02-19 2013-11-05 Matthew John During Peroral gene therapy of diabetes and obesity

Also Published As

Publication number Publication date
JP2004500104A (ja) 2004-01-08
US20120142760A1 (en) 2012-06-07
AU784499B2 (en) 2006-04-13
NZ521199A (en) 2004-11-26
JP5291278B2 (ja) 2013-09-18
EP1274464B1 (de) 2011-09-21
CN102151337A (zh) 2011-08-17
EP2298357A1 (de) 2011-03-23
US20080120734A1 (en) 2008-05-22
DK1274464T3 (da) 2012-01-23
CA2403205A1 (en) 2001-09-20
CN102151337B (zh) 2014-03-12
AU5057501A (en) 2001-09-24
WO2001068828A2 (en) 2001-09-20
ES2374061T3 (es) 2012-02-13
EP1274464A2 (de) 2003-01-15
WO2001068828A3 (en) 2002-06-13
US20020155100A1 (en) 2002-10-24
US7335646B2 (en) 2008-02-26

Similar Documents

Publication Publication Date Title
EP2302034A3 (de) Verbesserte Verfahren zur Neuprogrammierung von sommatischen Tierzellen
DK1274464T3 (da) Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
WO2003040346A3 (en) Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
ATE332142T1 (de) Zusammensetzungen zur behandlung von tierischen krankheiten und syndromen mit transferfaktor
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
EP1608299A4 (de) Implantatablage-technologien
DE60233805D1 (de) Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
SG144689A1 (en) Embryonic stem cells and neural progenitor cells derived therefrom
ATE258072T1 (de) Biologisches gelenkkonstrukt
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
EP1404811A4 (de) Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose
WO2002051980A3 (en) In vitro-derived adult pluripotent stem cells and uses therefor
MX9301840A (es) Tejido embriogenico y metodo para su produccion.
ATE494358T1 (de) Vorrichtung und verfahren zur fermentation in hohen zelldichten
WO2005094553A3 (en) Compositions for promoting bone growth and methods thereof
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
ATE535231T1 (de) Verfahren zur herstellung von poly-iclc und seine verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties